Core Viewpoint - Beihai Kangcheng-B (01228) experienced a significant stock price increase of over 12% following the release of its interim results, indicating positive market sentiment despite a decline in revenue [1] Financial Performance - For the first half of the year, the company reported revenue of 22.248 million, a decrease of 50.33% year-on-year [1] - The company achieved a profit of 59.238 million, compared to a loss of 247 million in the same period last year, marking a turnaround to profitability [1] - Revenue decline was primarily attributed to the company's strategic focus on rare diseases initiated in 2021, with the termination of the distribution agreement for the product "He Li An" in Taiwan by the end of 2024 [1] - Excluding the sales of "He Li An" in Taiwan, the company's revenue decreased by 1.7 million or 6.9% compared to the same period in 2024, mainly due to proactive inventory management and reduced stock of "Mai Ru Bei" in the channels [1] Strategic Developments - In August 2025, the company announced a share subscription agreement with Baiyang Pharmaceutical, where Baiyang will invest 100 million Hong Kong dollars to subscribe for shares in Beihai Kangcheng [1] - The agreement includes an exclusive commercialization service contract, enhancing strategic collaboration between the two companies [1] - A subsidiary of Baiyang Pharmaceutical will gain promotional rights for specific products of Beihai Kangcheng in mainland China, Hong Kong, and Macau [1]
港股异动 | 北海康成-B(01228)绩后涨超12% 公司上半年实现扭亏为盈 近期与百洋医药达成战略合作